Lp(a) Hypothesis Unproven at Phase 3: Pelacarsen Failure Resets the Entire Field

Pelacarsen Phase III Lp(a)HORIZON Trial Misses Primary Endpoint

Novartis announced that its pelacarsen Phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint. The trial aimed to reduce the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization, in over 8,000 patients with elevated Lp(a) and established cardiovascular disease. Despite achieving lower lipoprotein (a) levels with pelacarsen, this did not translate into reduced cardiovascular risk in the overall study population. The findings, while not as hoped, provide important new evidence for scientific understanding of Lp(a) lowering and cardiovascular outcomes.

• The Lp(a)HORIZON trial's primary endpoint, a composite of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization, was not met by pelacarsen compared to placebo. This indicates that the observed Lp(a) lowering did not result in a statistically significant reduction in cardiovascular risk in the overall study population.
• Despite the failure to meet the primary endpoint, pelacarsen successfully achieved lower lipoprotein (a) (Lp(a)) levels in the study participants. This confirms the drug's intended mechanism of action in reducing Lp(a) production, even though the clinical benefit on MACE was not demonstrated in this trial.
• The Lp(a)HORIZON trial was a large-scale, pioneering cardiovascular outcomes study involving 8,323 patients with elevated Lp(a) and established cardiovascular disease, all of whom were already receiving optimized, guideline-directed treatments. The results, though negative for the primary endpoint, contribute significant scientific evidence to the understanding of Lp(a) lowering and its potential impact on residual cardiovascular risk beyond current standard care.

The Persistent Challenge of Elevated Lp(a) in CVD

Elevated Lp(a) presents a distinctive therapeutic challenge: its levels are genetically determined and minimally affected by conventional treatments for hypercholesterolemia and hypertriglyceridemia, leaving a substantial proportion of high-risk patients without adequate lipid control. While novel RNA-directed therapies and other targeted agents have demonstrated efficacy in reducing Lp(a) levels, several structural, clinical, and evidentiary gaps continue to constrain optimal management.

• Resistance to conventional lipid-lowering therapy. Lp(a) levels are largely unresponsive to standard pharmacological approaches, including statins, ezetimibe, and fibrates. Even PCSK9 inhibitors such as alirocumab and evolocumab, which achieve LDL-C reductions of up to 62%, offer only partial Lp(a) reduction and do not address the genetically determined burden of elevated Lp(a) as a primary target.

• No approved Lp(a)-specific pharmacotherapy. Currently, no drug has been officially approved for lowering Lp(a) levels. Investigational agents — including the antisense oligonucleotide pelacarsen and the siRNA agents olpasiran, zerlasiran, and lepodisiran — remain in clinical development, with phase 3 cardiovascular outcomes trials ongoing for some. The oral small-molecule inhibitor muvalaplin represents an additional investigational option but has not yet received regulatory approval.

• Absence of cardiovascular outcomes data for novel agents. Although RNA-directed therapies have demonstrated potent Lp(a) reductions in phase 1 and 2 trials — with olpasiran achieving a mean difference of -92.1% (95% CI -100.1 to -84.0%) and pelacarsen -54.2% (95% CI -72.2 to -36.2%) — outcomes data confirming reduction in major adverse cardiovascular events remain the "next frontier" of Lp(a) trials. Evidence-based guidelines on Lp(a) reduction in daily clinical practice are urgently needed following the results of phase 3 trials.

• Limitations of lipoprotein apheresis as the primary non-pharmacological option. Lipoprotein apheresis (LA) is currently the only available therapy capable of effectively reducing elevated Lp(a) levels in clinical practice, and has been shown to reduce major coronary events by 83% and non-coronary events by 63% in Lp(a)-indicated patients. However, its high cost, invasive extracorporeal nature, and requirement for repeated sessions significantly limit uptake and restrict its use to carefully selected patients who are refractory or intolerant to lipid-lowering medications, or who have progressive cardiovascular disease despite maximal drug therapy.

• Lack of standardized Lp(a) quantification methodology. An ideal Lp(a) quantification method — specifically, an apo(a) isoform-independent assay with appropriate calibrators reporting Lp(a) levels in molar units — has not yet been established or universally adopted, complicating both risk stratification and the interpretation of treatment response across trials and clinical settings.

• Baseline Lp(a) levels modify treatment response. Network meta-analysis data indicate that baseline Lp(a) levels significantly modify treatment response (P < 0.001), adding complexity to patient selection and the generalizability of trial results to heterogeneous real-world populations.

• Insufficient real-world and registry evidence. National and international registries compiling outcome data for lipoprotein apheresis need to be established to expand the evidence base regarding its effectiveness. Similarly, real-life data on LA efficacy in special populations — such as pregnant women with elevated Lp(a) and high cardiovascular risk — remain limited.

Unpacking the Lp(a)HORIZON Trial Design and Outcomes

Several randomized, controlled trials have evaluated Lp(a)-lowering agents across distinct patient populations, employing varied dosing regimens and endpoints to characterize both efficacy and safety. The trials below span antisense oligonucleotide (ASO), small interfering RNA (siRNA), and small-molecule approaches, collectively informing the therapeutic landscape for elevated Lp(a) in the setting of established or high-risk cardiovascular disease.

Implications for the Antisense Oligonucleotide Lp(a) Landscape

Pelacarsen operates as a liver-specific antisense oligonucleotide (ASO) targeting apolipoprotein(a) synthesis to reduce circulating Lp(a) — a mechanism shared in principle by the broader class of RNA-based Lp(a)-lowering agents. Several small interfering RNA (siRNA) candidates targeting the same indication (elevated Lp(a) and associated ASCVD risk) are in active clinical development, each employing GalNAc-conjugated hepatic gene silencing to inhibit apo(a) synthesis.

The knowledge base does not have sufficient information on this aspect. regarding the specific intervention models (e.g., parallel-group, crossover) for the olpasiran phase 3 trial and the lepodisiran phase 3 trials beyond what is noted above.

Lp(a) Lowering: A Setback for Broad Cardiovascular Prevention

For years, elevated lipoprotein(a) (Lp(a)) has been recognized as an independent, genetically determined, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis. This understanding fueled the development of novel therapies, with pelacarsen, an antisense oligonucleotide (ASO), emerging as a frontrunner due to its ability to significantly reduce Lp(a) levels in earlier trials. The Lp(a)HORIZON Phase III trial was designed as a pivotal cardiovascular outcomes study, enrolling over 8,000 patients with established CVD and elevated Lp(a), aiming to definitively prove that lowering Lp(a) translates into a reduction in major adverse cardiovascular events (MACE).

The recent announcement that Lp(a)HORIZON did not meet its primary endpoint, despite pelacarsen effectively lowering Lp(a) levels, marks a critical juncture for the field. This outcome challenges the straightforward assumption that reducing Lp(a) will directly lead to improved cardiovascular outcomes in a broad population with existing disease. It suggests that the relationship between Lp(a) reduction and MACE prevention may be more complex than initially hypothesized, or that the magnitude or duration of lowering, or the patient population studied, was not optimal.

This development carries several implications:

• Re-evaluation of the Lp(a) Hypothesis: While Lp(a) remains a causal risk factor, its modifiability for MACE reduction in a general CVD population now requires deeper scientific scrutiny.

• Patient Selection: Future research may need to focus on identifying more specific patient subgroups, potentially those with extremely high Lp(a) levels (beyond the ≥70 mg/dL or ≥90 mg/dL thresholds in Lp(a)HORIZON) or those with particular comorbidities where Lp(a) plays a more pronounced role, such as certain stages of chronic kidney disease where statins are less effective.

• Impact on Pipeline: Other RNA-based therapies (siRNA, other ASOs) targeting Lp(a) will face increased pressure to demonstrate clear clinical benefit, potentially leading to more stringent trial designs or a shift in target indications.

The scientific community will now meticulously dissect the Lp(a)HORIZON data to understand why Lp(a) lowering did not translate into MACE reduction. This setback, while disappointing, provides invaluable insights that will undoubtedly shape the future of Lp(a)-targeted therapies, guiding the development of more refined strategies to address this persistent cardiovascular risk factor.